Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,836 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- C Clear all

Conditions: Diabetes Mellitus
Interventions: ruboxistaurin, placebo; Drug · Other
Lead sponsor: Chromaderm, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Exercise-induced Bronchospasm
Interventions: Vitamin C, Placebo; Dietary Supplement · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hyperuricemia
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: AMG 691, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Lake Forest, California • Aventura, Florida • Palmetto Bay, Florida + 12 more

Conditions: Healthy Volunteers
Interventions: BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Subjects, Pharmacokinetics of ASP015K
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more

Conditions: Focus of the Study: Safety of XFB19
Interventions: XFB19, Placebo; Drug
Lead sponsor: Xfibra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pharmacokinetics and Safety of Elevated Doses
Interventions: teduglutide, tedguglutide; Drug
Lead sponsor: Shire; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: COPD, Inflammation
Interventions: simvastatin; Drug
Lead sponsor: VA Loma Linda Health Care System; Federal
Eligibility: 40 Years to 79 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Rheumatoid Arthritis
Interventions: Lovastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Hypercholesterolemia
Interventions: AZD8233; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Fatty Liver Disease
Interventions: JNJ-75220795, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Hollywood, Florida • San Antonio, Texas

Conditions: Asthma
Interventions: Placebo, Primatene Mist, Epinephrine inhalation; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Costa Mesa, California • Los Angeles, California • Orange, California + 24 more

Conditions: Keratoconus
Interventions: Antioxidants (Vitamins A,C,E) plus GSH, Placebo, Centrum, Dietary Sources; Other · Dietary Supplement · Combination Product
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Steatohepatitis
Interventions: AZD7503; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Chandler, Arizona • Montclair, California • Hialeah, Florida + 5 more

Conditions: Diabetes Mellitus Type 2
Interventions: PF-07081532, Placebo, Clopidogrel; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Anaheim, California • South Miami, Florida

Conditions: Healthy Volunteer
Interventions: BIIB144, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Chronic Pancreatitis
Interventions: Prolastin-C, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more

Conditions: Gastroesophageal Reflux Disease
Interventions: AZD3355, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Vitamin D Deficiency
Interventions: Redoxon VI, placebo; Dietary Supplement
Lead sponsor: Oregon State University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Type 2 Diabetes
Interventions: INCB019602, Placebo, Metformin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more

Search by objective public record fields.

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Vitamin C & Exercise Induced Bronchoconstriction (EIB)

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide

Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Safety Study in Adolescent and Adult Patients With Asthma

The Role of Antioxidant Supplementation in Keratoconus Patients

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes